Mercaptopurin Silver Pharma

Mercaptopurine Monohydrate, the active ingredient in Mercaptopurin Silver Pharma, is a purine antimetabolite presented as an oral tablet for oral use. It is employed in the treatment of acute lymphoblastic leukemia and as an immunosuppressant in inflammatory bowel disease, helping to control abnormal cell proliferation and immune response.

GNH USA supplies Mercaptopurin Silver Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mercaptopurine is used in conditions that involve abnormal lymphoid proliferation or immune‑mediated inflammation. - Acute lymphoblastic leukemia (maintenance): prolongs remission by suppressing leukemic cell growth. - Acute lymphoblastic leukemia (induction): contributes to achieving complete remission as part of combination chemotherapy. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): reduces intestinal inflammation through immunosuppression.

Mercaptopurine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes after dosing. - Loss of appetite: reduced food intake. - Fatigue: general tiredness. - Leukopenia: decreased white blood cell count. - Elevated liver enzymes: mild hepatic irritation.

Serious or Rare Side Effects: - Severe bone marrow suppression: pancytopenia requiring medical intervention. - Pancreatitis: acute inflammation of the pancreas. - Hepatotoxicity: significant liver injury. - Opportunistic infections: due to immunosuppression. - Hypersensitivity reactions: rash, fever, or anaphylaxis. - Secondary malignancies: rare long‑term risk of other cancers.

Before initiating therapy, several safety considerations are recommended. - Blood monitoring: regular CBC to detect leukopenia or anemia. - Liver function tests: assess hepatic enzymes periodically. - Renal function: evaluate creatinine clearance for dose adjustment. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - TPMT deficiency: test for enzyme activity to prevent toxicity. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mercaptopurine interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol: markedly increases mercaptopurine toxicity. - Azathioprine: additive myelosuppression. - Warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Methotrexate: combined effect on bone marrow. - Trimethoprim‑sulfamethoxazole: may increase risk of myelosuppression. - Ribavirin: potential for enhanced hematologic toxicity.